173 related articles for article (PubMed ID: 23807564)
1. PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers.
Du QQ; Wang ZJ; He L; Jiang XH; Wang L
Eur J Clin Pharmacol; 2013 Nov; 69(11):1917-25. PubMed ID: 23807564
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
3. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
He J; Qiu Z; Li N; Yu Y; Lu Y; Han D; Li T; Zhao D; Sun W; Fang F; Zheng J; Fan H; Chen X
Eur J Clin Pharmacol; 2011 Jul; 67(7):701-7. PubMed ID: 21327909
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.
Ruzilawati AB; Gan SH
Pharmacology; 2010; 85(6):357-64. PubMed ID: 20523106
[TBL] [Abstract][Full Text] [Related]
5. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
[TBL] [Abstract][Full Text] [Related]
6. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
9. The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.
Fan L; Zhou G; Guo D; Liu YL; Chen WQ; Liu ZQ; Tan ZR; Sheng D; Zhou HH; Zhang W
Clin Pharmacokinet; 2011 Sep; 50(9):605-11. PubMed ID: 21827215
[TBL] [Abstract][Full Text] [Related]
10. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.
Svärd J; Spiers JP; Mulcahy F; Hennessy M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):536-49. PubMed ID: 20861742
[TBL] [Abstract][Full Text] [Related]
11. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
Bidstrup TB; Damkier P; Olsen AK; Ekblom M; Karlsson A; Brøsen K
Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
[TBL] [Abstract][Full Text] [Related]
12. The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.
Xiang Q; Cui YM; Zhao X; Yan L; Zhou Y
Pharmacology; 2012; 89(1-2):105-10. PubMed ID: 22398664
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
Pei Q; Liu JY; Yin JY; Yang GP; Liu SK; Zheng Y; Xie P; Guo CX; Luo M; Zhou HH; Li X; Liu ZQ
Eur J Clin Pharmacol; 2018 Aug; 74(8):1021-1028. PubMed ID: 29748863
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
Huwyler J; Wright MB; Gutmann H; Drewe J
Curr Drug Metab; 2006 Feb; 7(2):119-26. PubMed ID: 16472102
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.
Bidstrup TB; Stilling N; Damkier P; Scharling B; Thomsen MS; Brøsen K
Eur J Clin Pharmacol; 2004 Apr; 60(2):109-14. PubMed ID: 15034704
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers.
Oliver P; Lubomirov R; Carcas A
Clin Chem Lab Med; 2010 May; 48(5):635-9. PubMed ID: 20218903
[TBL] [Abstract][Full Text] [Related]
18. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
Hatorp V; Hansen KT; Thomsen MS
J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
[TBL] [Abstract][Full Text] [Related]
19. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme.
Wang XD; Li JL; Su QB; Guan S; Chen J; Du J; He YW; Zeng J; Zhang JX; Chen X; Huang M; Zhou SF
Br J Clin Pharmacol; 2009 Feb; 67(2):255-61. PubMed ID: 19173680
[TBL] [Abstract][Full Text] [Related]
20. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Niemi M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]